Amarin Corp Plc (AMRN)

[HDGabor]

From BD: "It was stated that before an indication would be entertained for Ethyl-EPA as
add-on to statin therapy in patients with elevated TG levels, the applicant at a minimum
would have to provide results from a 12-week study with lipid endpoints as well as
initiate an appropriately designed cardiovascular outcomes study. This outcomes study,
known as REDUCE-IT, is ongoing and is investigating whether the addition of AMR101
4 g daily ameliorates residual cardiovascular risk among patients at high CV risk who
have moderate hypertriglyceridemia at LDL-C goal on statin therapy. The study designs
for both ANCHOR and REDUCE-IT were agreed to by the Division under special
protocol assessments."